All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021;8(10):e688-e699.
Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol. 2021.
Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy. Stem Cell Res. 2021;53:102278..
Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Commun (Lond). 2021..
A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Adv. 2021.
A scoring system for predicting the prognosis of late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.
Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia. Chin Med J (Engl). 2021;134(20):2518-2520.
cGVHD in pediatric haplo-HSCT. Biol Blood Marrow Transplant. 2020..
DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. Br J Haematol. 2020.
Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. Transpl Infect Dis. 2020:e13544.
Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020;8(1).
The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.
The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr Transplant. 2020:e13793..
The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020..
Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020.
Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study. Am J Hematol. 2020.
A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets. 2020:1-9.
Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2019.
Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19. Biol Blood Marrow Transplant. 2019.
Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (. Biol Blood Marrow Transplant. 2019.
Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractor. Biol Blood Marrow Transplant. 2019.
Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3(24):4312-4325.